MACNICA,-INC.
7.11.2016 11:02:05 CET | Business Wire | Press release
Macnica, Inc., a global leader in distributing semiconductors, electronic components, and network equipment, with its headquarter located in 1-6-3 Shin-Yokohama, Kohoku-ku, Yokohama, Japan (“Macnica”), today expanded its Mpression IP portfolio releasing SLVS-EC interface IP core for ALTERA FPGA compliant with SLVS-EC interface technology newly incorporated into Sony CMOS Image Sensor. Users can quickly develop and introduce their products early into market with SLVS-EC technology.
Macnica is a global, technology oriented distributor particularly focusing on demand creation. Macnica not only offers outstanding technical support for its product lines but also provides its original products and services under its “Mpression” brand for satisfying customer needs and solving issues.
Sony CMOS Image Sensor with SLVS-EC interface capable of high speed data
transfer will be introduced into CMOS Image Sensor market to satisfy
needs for trending higher resolution and higher framerate.
Mpression
SLVS-EC Rx IP Macnica has developed can support and contribute users who
develop advanced products supporting SLVS-EC interface.
Macnica has paid attention to SLVS-EC interface in the early days and
realized a world first solution to receive high speed image data
transmitted over SLVS-EC interface on ALTERA FPGA.
Now, the IP
enables to connect Sony high resolution and high framerate CMOS Image
Sensor to FPGA easily. It is ideal for a various applications like the
products with CMOS image sensor and FPGA to receive the image data.
Macnica is licensing the IP worldwide through its subsidiaries or
partners. ATD Electronique, an affiliate of Macnica sells and supports
it in Europe.
Macnica will exhibit demonstration of SLVS-EC Rx IP
at the booth of ATD Electronique in VISION SHOW held in Stuttgart,
Germany from November 8 to 10. Please don’t forget to visit us.
|
VISION SHOW Information |
||
| Name of Exhibition |
VISION
Leading world trade fair for machine vision |
|
| Schedule | 08 - 10 November 2016 | |
| Place | Messe Stuttgart | |
| Booth No. of ATD Electronique | Hall 1, E82 | |
* All company names and product names mentioned herein are trademarks or registered trademarks of their respective owners.
About Macnica:
Macnica has been established since 1972 as a semiconductor distribution company headquartered in Yokohama, Japan servicing customers in Japan, the Americas and Asia through its 75 sales offices around the world. Total number of employees is over 2,000 worldwide and total revenue for fiscal 2015 was approximately US$4B. Macnica is famous for having an excellent engineering team of more than 800 application engineers with strong focus on providing technical support for its customers. Macnica is continuing to improve its presence globally by having successful partners in strategic areas in the electronics market. Macnica Inc. and ATD Electronique have entered into an agreement for Macnica to acquire 49% of ATD’s outstanding shares on July 22nd, 2016.
About ATD Electronique:
ATD Electronique, who was founded in 1990 represents and distributes innovative electronic component brands and offers engineering services for machine vision and imaging applications through its offices in France and Germany and its representatives in Italy and Spain. Its product portfolio includes image sensors, controller & interface ICs, ISPs as well as development tools and design services enabling fast and efficient realization of new high performance camera systems for markets such as automotive, medical, security and machine vision.
About Mpression:
Mpression represents an integration and collection of all original
technology solutions of Macnica group such as software, platforms,
evaluation boards, and others which has been developed, provided and
supported in each country by each Macnica group companies.
Macnica
provides its advanced and ready-to-use system level solutions to
customers based on the accumulated know-hows by the very experienced
engineers from worldwide group companies, and thus leads to maximizing
the value of products as well as shortening customer's development time.
Macnica
is going to propose and support the IP offering one-stop services
through its group companies in all regions from country to country in
Europe, USA, China, and Asia.
Please visit our web-site (http://m-pression.com/
)
for a full detail of Mpression.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005041/en/
Contact:
Macnica, Inc.
Hajime Nakamura, 81-45-470-9838
Sales Planning,
Advanced Technology
AtdSpl@macnica.co.jp
FAX:
81-45-470-9857
Macnica Bldg No.2, 1-5-5 Shin-Yokohama, Kouhoku-ku,
Yokohama, 222-8563 JAPAN
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
